Laurus Labs forms JV company
KRKA holds 51% and Laurus Labs holds 49% shareholding
KRKA holds 51% and Laurus Labs holds 49% shareholding
The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Subscribe To Our Newsletter & Stay Updated